. Tumor cell-targeted delivery of CRISPR/Cas9 by aptamerfunctionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma. Biomaterials, 147,[68] [69] [70][71][72][73][74][75][76][77][78][79][80][81][82][83][84][85]. https://doi.Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma, Biomaterials (2017), Abstract 33 34 Osteosarcoma (OS) is a highly aggressive pediatric cancer, characterized by frequent lung metastasis 35 and pathologic bone destruction. Vascular endothelial growth factor A (VEGFA), highly expressed in OS, 36 not only contributes to angiogenesis within the tumor microenvironment via paracrine stimulation of 37 vascular endothelial cells, but also acts as an autocrine survival factor for tumor cell themselves, thus 38 making it a promising therapeutic target for OS. CRISPR/Cas9 is a versatile genome editing technology 39 and holds tremendous promise for cancer treatment. However, a major bottleneck to achieve the 40 therapeutic potential of the CRISPR/Cas9 is the lack of in vivo tumor-targeted delivery systems. Here, 41
supplemented with 10% fetal bovine serum (FBS) and 100 units ml -1 penicilin-streptomycin. Mouse 104 normal hepatocytes (AML12, ATCC) was cultured in a 1:1 mixture of DMEM and Ham's F12 medium 105 supplemented with 0.005 mg ml -1 insulin, 0.005 mg ml -1 transferrin, 5 ng ml -1 selenium, and 40 ng ml -1 106 dexamethasone, as well as 10% FBS and 100 units ml -1 penicilin-streptomycin. Human osteosarcoma Leibovitz's L-15 medium supplemented with 10% FBS and 100 units ml -1 penicilin-streptomycin. All the 118 above cells were negative for bacteria, yeast, fungi and mycoplasma. 119 120
Synthesis of library, primers and aptamers 121
The ssDNA library contained 30 random nucleotides flanked by fixed regions 122 5'-GCAATGGTACGGTACTTCC-30nt-CAAAAGTGCACGCTACTTTGCTAA-3'.
A forward primer 123
(5'-GCAATGGTACGGTACTTCC-3') and a reverse primer (5'-TTAGCAAAGTAGCGTGCACTTTTG-3' 124 were used in the PCR reaction for synthesis of double-stranded DNA (dsDNA) with equal length. The 125 forward primer (5'-GCAATGGTACGGTACTTCC-3') and another reverse primer with a GC-rich reverse 126 repeated sequence (underlined) at 5' terminus 127 amplification were performed at 95 °C for 60 s, 37 °C for 30 s, and 58 °C for 40 s, followed by 5 min 140 extension at 58 °C. ssDNA with unequal length was i solated from PCR products by electrophoresis in a 141 10% polyacrylamide-7M urea gel and the lower band of interest was purified from the gel for the next 142 round of selection [34] . 143 144 2.4. The synthetic ssDNA library (1500 pmol for initial round; 400 pmol for subsequent rounds) dissolved in 146 400 µl binding buffer [PBS with 0.1 mg ml -1 yeast tRNA (Sigma), 0.1 mg ml -1 salmon sperm DNA 147 (Invitrogen) and 1.0 mM MgCl 2 (Sigma)] was denatured by heating at 95 °C for 5 m in and then cooled on 148 ice for 10 min. The denatured library was incubated with 1-2 × 10 6 target cells at 37 °C for 0.5-1 h (1 h 149 for the first 6 cycles and 0.5 h for the left cycles). The cells were centrifuged and then washed with 150 washing buffer [PBS with 1.0 mM MgCl 2 (Sigma)]. The cell-bound ssDNA was eluted by heating at 95 °C 151
for 5 min and used as template for unequal length strand PCR reaction to generate the desired ssDNA. 152
The negative selection was introduced from the second round of cell-SELEX. The enriched ssDNA pool 153 was incubated with negative cells at 37 °C for 1 h. After centrifugation, the supernatant with cell-unbound 154 ssDNA was desalted and amplified by unequal length strand PCR. After multiple rounds of selection, the 155 final enriched ssDNA pool was PCR-amplified for the synthesis of dsDNA with equal length and cloned 156 into pMD-18T vector (Takara) [35] . Cloned sequences were determined in Sangon Co Ltd, Shanghai, 157
China. Secondary structures of aptamers were predicted by RNAstructure 5.6 software. Truncation was 158 performed to remove the non-critical bases in fixed regions of each sequence based on the predicted 159 secondary structures [33, 34] . 160 161
Binding assay in cell-SELEX 162
FAM-labeled ssDNA library, enriched pools or aptamer candidates at the indicated concentrations were 163 incubated with 2×10 5 cells in 400 µl binding buffer at 37 °C for 1 h. A fter washing, the cells were 164 re-suspended in 400 µl binding buffer. The mean fluorescence intensity was determined with a FACScan 165 cytometer (BD Immunocytometry Systems) by counting 20,000 events. The equilibrium dissociation 166 constants (K d ) of the aptamer-cell interactions were calculated by the equation Y = B max X/(K d + X) [36] . 167 168
Construction of CRISPR/Cas9 plasmids 169
Guide sequence oligos of 6 candidate gRNAs ( Supplementary Table 2 ) targeting VEGFA were from 170
GeCKOv2 libraries [37] and cloned into PX458 plasmids encoding Cas9 and gRNA scaffold. Non-sense 171 gRNA (target sequence: GAACAGTCGCGTTTGCGACT) was designed to have low homology to the 172 human or murine genome and used as negative control [38] . Briefly, two complementary 173 oligonucleotides with the guide oligos were annealed to generate dsDNA with overhangs on both ends 174 and ligated to the BbsI pre-digested PX458 plasmids for generation of CRISPR/Cas9 plasmids. A G-C 175 base pair was added at the 5' end of the guide sequence for U6 transcription, which did not adversely M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 7 2.7. Selection of the optimal VEGFA gRNA 180 K7M2 cells were seeded in 6-well plates, 25 cm 2 flasks or Nunc glass bottom dishes at appropriate 181 densities and incubated overnight until 70%-80% confluence in DMEM supplemented with 10% FBS at 182 37°C. The cells were transfected with different CRI SPR/Cas9 plasmids in FBS-free DMEM using 183
Lipofectamine 3000. After 8 h, the transfection medium was replaced with fresh DMEM supplemented 184 with 10% FBS and the cells were cultured for an additional 48 h. To select the optimal VEGFA gRNA, 185
Cas9 and EGFP expression was determined by western blotting and confocal imaging, respectively. 186 Indels was examined by Surveyor assay [40] and confirmed by sequencing analysis [39] . Levels of 187 VEGFA in both cell lysates and supernatants were tested by ELISA. Off-target sites were predicted by 188 online CRISPR design tool (http://crispr.mit.edu/) and indels for the off-target sites were determined by 189
Surveyor assay. vacuum, yielding a highly viscous material. To isolate the PPC hydrochloride and remove unreacted 208 starting materials from products, the concentrated mixture was mixed with acetone (< 0.4% water) and 209 stirred leading to PPC hydrochloride precipitation as a free-flowing material. Following precipitation, the 210 supernatant liquid was discarded. The washing step was repeated to ensure complete removal of 211 residual reaction. PPC-CRISPR/Cas9 complexes were generated by firstly preparing PPC and 212 CRISPR-Cas9 plasmids at appropriate concentrations in 10% lactose respectively. The plasmids 213 solution was then added dropwise with stirring to the PPC solution at the nitrogen of PPC/phosphate of 214 plasmids (N/P) molar ratio of 11: 1 and incubated for 15 min at room temperature to form the complexes. Sepharose CL-4B column, using HBS (pH 7.4) as a running buffer to remove unconjugated micelles and 221 chemical reagents [36] . NTS GmbH, D-Oberkochen). The frozen specimen was then transferred via a cryo-transfer unit (Gatan 244 626-DH) to a transmission electron microscope (FEI/Philips Tecnai 12 Bio TWIN) with a pre-cooled 245 cryo-specimen holder [36] . (5) Serum stability: Serum stability of 3' thiol-and 2'-O-methyl-modified LC09 246 and CRISPR/Cas9 plasmids encapsulated in PPC were assessed by electrophoresis at 0, 2, 4, 6, 12, 247 and 24 h. Briefly, 3' thiol-and 2'-O-methyl-modified LC09 and PPC-CRISPR/Cas9 were incubated with 248 50% FBS at 37°C. After 0, 2, 4, 6, 12 and 24 h, PPC -CRISPR/Cas9 sample was treated with dextran 249 sulfate for decomplexation. 3' thiol-and 2'-O-methyl-modified LC09 sample and PPC-CRISPR/Cas9 250 sample with decomplexation were loaded onto 2% agarose gels for electrophoresis. The free LC09 251 aptamer and CRISPR/Cas9 plasmids served as negative controls [36] . 252 253 2.10. Cellular uptake of different CRISPR/Cas9 formulations 254 OS cells were seeded in 6-well plates at appropriate densities and cultured overnight until 70%-80% 255 confluence in DMEM supplemented with 10% FBS at 37 °C. The cells were incubated with different 256
Cy5-labeled CRISPR/Cas9 formulations in FBS-free DMEM including PPC-CRISPR/Cas9,
cytometer (BD Immunocytometry Systems) by counting 20,000 events. OS cells without any incubation 260 were performed as a blank control to measure background signals, which were subtracted from the final 261 calculations [36] . 262 263
In vitro treatment of OS cells with different CRISPR/Cas9 formulations 264
OS cells were seeded in 6-well plates, 96-well plates, 25 cm 2 flasks or Nunc glass bottom dishes 265 (Thermo Fisher Scientific) at appropriate densities and cultured overnight until 70%-80% confluence in 266 DMEM supplemented with 10% FBS at 37°C. The cells w ere incubated with vehicle (PBS) or different 267 CRISPR/Cas9 formulations in FBS-free medium. After 8 h, the medium was replaced with fresh medium 268 supplemented with 10% FBS and the cells were continuously cultured to determine CRISPR/Cas9 269 expression, genome editing, cell viability, migration and invasion. For migration of OS cells treated with vehicle (PBS) or different CRISPR/Cas9 formulations, a wound 306 area was carefully created by scraping the cell monolayer with a sterile 10 µl pipette tip. After being 307 washed three times with PBS, scratches were photographed as the baseline. Subsequently, the cells 308 were cultured in DMEM supplemented with 10% FBS for another 48 h. For migration of endothelial cells, 309 the cells were seeded in 6-well plates at appropriate densities and cultured overnight until 70%-80% 310 confluence in endothelial cell growth medium at 37 °C. A wound area was carefully created by scraping 311 the cell monolayer with a sterile 10 µl pipette tip. After being washed three times with PBS, scratches 312 were photographed as the baseline. Then, the endothelial cell growth medium was changed to 313 conditioned medium from OS cells and cultured for another 18 h. The width of the wound area was 314 monitored with an inverted microscope [43] . 315 316
CCK-8 assay 317
Cell viability of OS cells and proliferation of endothelial cells were examined by the CCK-8 (Beyotime 318
Inst Biotech) according to manufacturer's instructions. For OS cells, 5 × 10 3 cells per well were seeded 319 in 96-well plates and cultured for 24 h. Then, the cells were treated with vehicle (PBS) or different 320 CRISPR/Cas9 formulations. For endothelial cells, 5 × 10 3 cells per well were seeded in 96-well plates 321 and cultured for 24 h. Then, the cells were treated with different conditioned medium from OS cells. After 322 48 h, 10 µl WST-8 dye was added to each well and the cells were incubated at 37 °C for 3 h and the 323 absorbance was determined at 450 nm using a microplate reader [44] . 324 325 2.17. Surveyor assay 326 OS cells were treated with different CRISPR/Cas9 as described above. Cells were incubated at 37 ºC for 327 48 h post treatment before genomic DNA extraction. Genomic DNA was extracted using the 328 QuickExtract DNA extraction kit (Epicentre) following the manufacturer's protocol. Briefly, cells were 329 resuspended in QuickExtract solution and incubated at 65 ºC for 15 min and 98 ºC for 10 min. Genomic 330 region surrounding the CRISPR target site for each gene was PCR amplified using the primers in 331 Supplementary Table 6 and products were purified using QiaQuick Spin Column (Qiagen) following 332 manufacturer's protocol. A total of 400 ng purified PCR products were mixed with 2 µl 10 × Taq Immunocytometry Systems) by counting 20,000 events [36] . OS tissues and tumor lung metastatic sites were dissected from mice and embedded in optimal cutting 416 temperature medium (O.C.T.). The cryosection (thickness: 5 µm) were cut in a freezing cryostat at -20 °C. 417
The sections were air dried at room temperature, fixed in ice-cold acetone for 10 min, permeabilized with M A N U S C R I P T
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13 incubated overnight at 4°C with a rabbit polyclonal antibody to Ezrin (Abcam). Following three washes in 420 PBS, the sections were incubated with Alexa Fluor ® 488-conjugated donkey anti-rabbit IgG (Abcam) for 421 1 h. The sections were mounted with medium containing DAPI (Abcam) and examined under a 422 fluorescence microscope (Q500MC Leica image analysis system). H&E staining was performed on the 423 adjacent sections for orientation [36] . 424 425 2.27. Immunohistochemistry 426 OS tissues and metastatic lungs dissected from mice were fixed with formalin and paraffin-embedded. 427
Immunohistochemical analyses were performed on 4 µm paraffin sections Sections were deparaffinized 428 using xylene and rehydrated in a series of decreasing concentrations of ethanol solutions. Heat-induced 429 epitope retrieval was carried out in citrate buffer (10 mM sodium citrate, pH 6.0) in a pressure cooker for 430 4 min. Endogenous peroxidase was blocked using a 3% hydrogen peroxide solution for 20 min. The 431 slides were washed with PBS and incubated with primary antibodies overnight at 4 °C. Primary 432 antibodies including a rabbit polyclonal antibody to VEGFA, a rabbit monoclonal antibody to Ki67, a 433 rabbit polyclonal antibody to Ezrin, a rabbit polyclonal antibody to MMP9 and a rabbit polyclonal antibody 434 to Survivin were from Abcam. After washing for three time, the sections were then incubated with 435 HRP-labeled second antibody for 1 h at room temperature. Colored reactions were developed using 
MicroCT analysis 455
The OS-bearing hindlimbs of mice from each group were scanned ex vivo with a microCT system 456 (vivaCT 40, SCANCO MEDICAL, Switzerland). The calibration was performed routinely in our lab using M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
14 movements during scanning. In total, 844 slices with a voxel size of 10 mm were scanned for the whole 460 OS-bearing hindlimbs. Bone destruction of the trabecular bone was analyzed after three-dimensional 461 reconstruction (sigma = 1.2, supports = 2 and threshold = 180) [36] . (Horiba ABX) [36] . 474 475
Statistical analyses 476
All numerical data are expressed as the mean ± standard deviation. Statistical differences among groups 477 were analyzed by one-way analysis of variance with a post-hoc test to determine group differences in the 478 study parameters. All statistical analyses were performed with SPSS software, version 22.0. Statistical 479 differences between two groups were determined by the Student's t test. P < 0.05 was considered 480 statistically significant. All the statistical data in this project were analyzed by a contract service from 481
Bioinformedicine (San Diego, CA, USA). We chose the representative images based on the 482 average/median level of the data for each group. For the in vivo experiments, sample size was 483 pre-determined by a power calculation. The mice were grouped randomly and blindly to researchers. 484
The mice in poor body condition before the experiments were excluded. 485
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT

Screening of OS cell-specific aptamers by cell-SELEX 488
We used highly metastatic mouse OS cells (K7M2) [52] as target cells to screen aptamers by 489 cell-SELEX from a library composed of 10 15 different ssDNA. Mouse normal hepatocytes (AML12) and 490 peripheral blood mononuclear cells (PBMCs) were chose as negative cells with the purpose of reducing 491 non-specific liver and PBMCs uptake after in vivo administration [36] . With increasing rounds of selection, 492
we observed progressively enhanced fluorescence intensity of fluorescein amidite (FAM)-labeled ssDNA 493 pools in K7M2 cells by flow cytometric analysis, whereas no obvious change of fluorescence intensity 494 was found in AML12 cells and PBMCs (Fig. 1a) . After 12 rounds of selection, we sequenced the highly 495 enriched ssDNA pool and chose twenty representative sequences (from 200 clones), on the basis of 496 their predicted secondary structures, for truncation to remove the non-critical bases [53] 497
( Supplementary Table 1 ). Flow cytometric analysis showed that three aptamer candidates (LC01, 498 LC07 and LC09) had good binding ability to K7M2 cells rather than AML12 cells, PBMCs (Fig. 1b) . To 499 minimize nuclease degradation, the aptamer candidates were modified with 2'-O-methyl-nucleotide 500 substitutions [54, 55] and the results showed that LC07 and LC09 still bound to K7M2 cells with high 501 affinity but not to AML12 cells and PBMCs (Fig. 1c) . In addition, LC07 and LC09 also bound to human 502 Fig. 1a) , 503
OS cells (Saos-2) but not to human normal liver cells (THLE-3) and PBMCs (Supplementary
implying their translational potentials in clinical application. Binding affinity of LC07 and LC09 with K7M2 504 cells, as quantified by equilibrium dissociation constants (K d ) [36] , was in the nanomolar-to-picomolar 505 range (Fig. 1d) . Finally, we chose LC09 for further studies due to its satisfactory secondary structure 506 with lower predicted free energy and the least base number (Fig. 1e) . We also evaluated the binding 507 ability of LC09 with another mouse OS cells (K12), primary mouse osteoblasts and human breast cancer 508 cells (MBA-MD-231), respectively. Results showed that LC09 aptamer recognized K12 cell rather than 509 other cells, indicating the high specificity of the LC09 aptamer on OS cells (Supplementary Fig. 1b) . 510 511 3.2. Selection of the optimal VEGFA gRNA for CRISPR/Cas9-based genome editing 512 6 candidate VEGFA gRNAs were chosen from GeCKOv2 libraries ( Supplementary Table 2 ) [37] . To 513 select the optimal gRNA, we constructed a series of CRISPR/Cas9 plasmids, which encoded different 514 candidate gRNAs, Cas9 and the enhanced green fluorescent protein (EGFP) (Supplementary Fig. 2a) . 515
After transfection of these CRISPR/Cas9 plasmids into mouse OS cells (K7M2) by Lipofectamine 3000 516 at the same concentration, we detectable comparable Cas9 protein levels (Supplementary Fig. 2b) and 517 EGFP fluorescence (Supplementary Fig. 2c ). However, Surveyor assay showed that insertion/deletion 518 (Indel) frequency of gRNA 2 was the highest among the 6 candidate gRNAs (Supplementary Fig. 2d) . 519
Levels of VEGFA in both lysates and supernatants of K7M2 cells transfected with CRISPR/Cas9 520 plasmids encoding gRNA 2 were the lowest, as determined by the enzyme-linked immunosorbent assay 521 (ELISA) (Supplementary Fig. 2e ). Sequencing analysis confirmed that gRNA 2 induced Indels at or 522 near the cleavage site of VEGFA alleles and the lengths of the indels were mainly at 1 base pair (bp) or 2 523 bp, which lead to frame-shift mutation of VEGFA (> 60%). (Supplementary Fig. 2f ). We also predicted M A N U S C R I P T
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showed that there was no obvious Indel frequency for the off-target sites (Supplementary Fig. 2g ). All 526 the above results indicated that gRNA 2 was the optimal gRNA for CRISPR/Cas9-based VEGFA 527 genome editing. 528 529
Preparation and in vitro characterization of LC09-PPC-CRISPR/Cas9 530
The preparation procedures for LC09 aptamer-functionalized CRISPR/Cas9 delivery system were 531
shown in Supplementary Fig. 3a . Briefly, CRISPR/Cas9 plasmids encoding gRNA 2, Cas9 and EGFP 532 were spontaneously encapsulated in PPC lipopolymer. The 3' thiol-and 2'-O-methyl-modified LC09 was 533 activated and conjugated to DSPE-PEG2000-Mal to form LC09-PEG2000-DSPE. Then, 534 LC09-PEG2000-DSPE was inserted into the surface of PPC encapsulating CRISPR/Cas9 plasmids, i.e., 535 LC09-PPC-CRISPR/Cas9. Laser light scattering demonstrated that LC09-PPC-CRISPR/Cas9 had the 536 diameter of 163.1 ± 17.2 nm (Supplementary Fig. 3b ) and the zeta potential of -12.7 ± 2.1 mV 537 Table 4 ). The particle size of LC09-PPC-CRISPR/Cas9 was appropriate for passive 538 tumor-targeting considering the more permeabilized blood vessels in tumor with the pore size ranging 539 from 100 nm to 780 nm compared to the normal pore size < 6 nm [56] . The encapsulation efficiency of 540 the CRISPR/Cas9 was above 80% and the loading efficiency of LC09 was 84.7 ± 8.7% for 541 LC09-PPC-CRISPR/Cas9 ( Supplementary Table 4 ). Representative image from cryogenic 542 temperature transmission electron microscopy (cryo-TEM) showed the uniformity of particle distribution 543 and a spherical shape (Supplementary Fig. 3c ). Both 2'-O-methyl-modified LC09 aptamer and 544 CRISPR/Cas9 plasmids encapsulated in PPC showed desirable serum stability at the examined time 545 points, when compared to their respective free forms (Supplementary Fig. 3d) , indicating the protection 546 role of PPC for DNA plasmids from serum enzyme degradation. 547 548
(Supplementary
In vitro cellular uptake, genome editing and anti-tumor activity 549
We labeled CRISPR/Cas9 plasmids with Cyanine 5 (Cy5) and investigated in vitro effects of LC09 550 aptamer on cellular uptake of the plasmids in OS cells (K7M2). A random sequence (Rd) served as the 551 negative control for the LC09 aptamer. Flow cytometric analysis showed the most intense fluorescence 552 signals in K7M2 cells treated with LC09-PPC-CRISPR/Cas9 when compared to PPC-CRISPR/Cas9, 553
Rd-PPC-CRISPR/Cas9 and positive control Lipo 3000-CRISPR/Cas9 (Lipofectamine 554 3000-CRISPR/Cas9) ( Fig. 2a) . Then, we examined the expression and genome editing of different 555 CRISPR/Cas9 formulations in K7M2 cells. Non-sense gRNA was used as a negative control for VEGFA 556 gRNA 2. Significantly higher levels of Cas9 protein, EGFP fluorescence and Indel frequency as well as 557 decreased VEGFA in both supernatants and lysates were observed in K7M2 cells treated with 558 LC09-PPC-CRISPR/Cas9 when compared to other PPC-based CRISPR/Cas9 formulation groups or 559
Lipo 3000-CRISPR/Cas9 (Supplementary Fig. 4; Fig. 2b and 2c) . In contrast to 560 LC09-PPC-CRISPR/Cas9, we found no obvious decrease of VEGFA in both supernatants and lysates of 561 K7M2 cells by LC09-PPC-CRISPR/Cas9 Ctrl, suggesting the specificity of the selected optimal gRNA 2 562
for VEGFA ( Fig. 2b and 2c) . (Supplementary Fig. 6a (Supplementary Fig. 6b) . Notably, reduction of 582 the fluorescence signals by inhibitors of macropinocytosis was more remarkable than that by inhibitors of 583 caveolae-mediated endocytosis, indicating that macropinocytosis was mainly responsible for cellular 584 uptake of LC09-PPC-CRISPR/Cas9. Macropinocytosis is an endocytosis pathway that permits bulk 585 uptake [57], which possibly led to efficient internalization of LC09-PPC-CRISPR/Cas9 (Supplementary  586   Fig. 6b) . 587 588 3.6. In vitro and ex vivo angiogenic activation by conditioned medium from OS cells 589 OS cells (K7M2) were treated with different CRISPR/Cas9 formulations and the conditioned medium 590 was collected. We incubated the mouse primary endothelial cells with the conditioned mediums to 591 determine their in vitro angiogenic activity, including proliferation, migration, invasion and tube formation 592 of endothelial cells [47, 58] (Fig. 3a) . Compared to conditioned medium from K7M2 cells after treatment 593 with vehicle (PBS), PPC-CRISPR/Cas9, Rd-PPC-CRISPR/Cas9 or LC09-PPC-CRISPR/Cas9 Ctrl, we 594 observed weaker proliferation, migration, invasion and tube formation of endothelial cells incubated with 595 conditioned medium from K7M2 cells after treatment with LC09-PPC-CRISPR/Cas9 (Fig. 3b-3e) . In 596 addition, reduced proliferation and tube formation of endothelial cells treated with conditioned medium 597 from another OS cell line K12 after treatment with LC09-PPC-CRISPR/Cas9 were also observed 598 ( Supplementary Fig. 7) . In addition, we performed ex vivo aortic ring assay [59, 60] to examine 599 angiogenic effects of the conditioned medium. receptors was designed as the tumor recognition element [73] . Nevertheless, CD44 is also highly 706 expressed in immune cells [74] and a potential concern regarding the targeting specificity still exists. 707
Here, we screened the LC09 aptamer specifically targeting both human and mouse OS cells. In vitro 708 data showed that LC09 has no binding ability to hepatocytes and PBMCs. Consistently, in vivo data 709 demonstrated that LC09 facilitated tumor cell-selective distribution and expression of CRISPR/Cas9 in 710 both orthotopic OS and lung metastasis and minimized liver accumulation of CRISPR/Cas9. 
